Santhera Pharmaceuticals (SPHDF) Stock Price, News & Analysis

Company Overview

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on developing and commercializing treatments for rare neuromuscular diseases. Its research and development activities have centered on conditions with significant unmet medical needs, including Duchenne muscular dystrophy (DMD) and mitochondrial disorders.

The company’s lead product is vamorolone, marketed in the United States under the brand name Agamree. Vamorolone is a corticosteroid analogue developed to help treat DMD while potentially reducing some of the long-term side effects associated with conventional corticosteroid therapy. Santhera received regulatory approval for the product in Europe and the United States and has pursued commercialization through regional partnerships, including an agreement covering North America.

Santhera was founded in 2004 and is headquartered in Switzerland. Its operations and commercial activities have primarily focused on Europe and North America, while the company has also developed partnerships to support broader international access to its medicines. Santhera has historically worked on treatments for mitochondrial diseases, including idebenone, before concentrating more heavily on neuromuscular disorders. The company is led by Chief Executive Officer Dario Eklund.

Key Stats

• Today's Range: $18.30 to $18.30
• 50-Day Range: $18.30 to $23.25
• 52-Week Range: $18.30 to $19.79
• Volume: N/A
• Average Volume: 1,521 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Santhera Pharmaceuticals Stock Analysis - MarketRank™

Santhera Pharmaceuticals scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Santhera Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Santhera Pharmaceuticals is -13.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Santhera Pharmaceuticals is -13.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Santhera Pharmaceuticals has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in Santhera Pharmaceuticals has recently decreased by 4.22%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Santhera Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Santhera Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.25

News Sentiment

Santhera Pharmaceuticals has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Santhera Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Santhera Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Institutions

8.23% of the stock of Santhera Pharmaceuticals is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:SPHDF
• CIK: N/A
• Web: www.santhera.com
• Phone: (161) 906-8950
• Fax: N/A
• Employees: 45
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A